A detailed history of Wells Fargo & Company transactions in Cassava Sciences Inc stock. As of the latest transaction made, Wells Fargo & Company holds 25,960 shares of SAVA stock, worth $687,420. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,960
Previous 17,550 47.92%
Holding current value
$687,420
Previous $216,000 253.7%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$9.57 - $35.08 $80,483 - $295,022
8,410 Added 47.92%
25,960 $764,000
Q2 2024

Aug 13, 2024

BUY
$12.35 - $26.11 $14,770 - $31,227
1,196 Added 7.31%
17,550 $216,000
Q1 2024

May 10, 2024

BUY
$18.44 - $26.41 $40,088 - $57,415
2,174 Added 15.33%
16,354 $331,000
Q4 2023

Feb 09, 2024

BUY
$12.64 - $30.11 $20,716 - $49,350
1,639 Added 13.07%
14,180 $319,000
Q3 2023

Nov 13, 2023

SELL
$16.64 - $25.32 $127,112 - $193,419
-7,639 Reduced 37.85%
12,541 $208,000
Q2 2023

Aug 15, 2023

BUY
$21.59 - $27.88 $207,004 - $267,313
9,588 Added 90.52%
20,180 $494,000
Q1 2023

May 12, 2023

BUY
$23.46 - $36.44 $172,853 - $268,489
7,368 Added 228.54%
10,592 $255,000
Q4 2022

Feb 13, 2023

SELL
$27.82 - $44.16 $9,848 - $15,632
-354 Reduced 9.89%
3,224 $95,000
Q3 2022

Nov 14, 2022

BUY
$16.33 - $51.06 $21,016 - $65,714
1,287 Added 56.18%
3,578 $150,000
Q2 2022

Aug 12, 2022

SELL
$17.22 - $38.47 $134,023 - $299,412
-7,783 Reduced 77.26%
2,291 $64,000
Q1 2022

May 16, 2022

SELL
$32.6 - $53.05 $985,367 - $1.6 Million
-30,226 Reduced 75.0%
10,074 $374,000
Q4 2021

Feb 14, 2022

BUY
$36.77 - $90.91 $545,041 - $1.35 Million
14,823 Added 58.18%
40,300 $1.76 Million
Q3 2021

Nov 15, 2021

BUY
$41.79 - $135.3 $434,448 - $1.41 Million
10,396 Added 68.93%
25,477 $1.58 Million
Q2 2021

Aug 16, 2021

SELL
$32.15 - $89.72 $603,873 - $1.69 Million
-18,783 Reduced 55.47%
15,081 $1.29 Million
Q1 2021

May 13, 2021

SELL
$7.09 - $87.95 $926,712 - $11.5 Million
-130,707 Reduced 79.42%
33,864 $1.52 Million
Q4 2020

Feb 09, 2021

BUY
$6.79 - $12.25 $728,471 - $1.31 Million
107,286 Added 187.28%
164,571 $1.12 Million
Q3 2020

Nov 05, 2020

BUY
$2.86 - $11.51 $43,125 - $173,559
15,079 Added 35.73%
57,285 $660,000
Q2 2020

Aug 13, 2020

BUY
$2.04 - $9.64 $80,394 - $379,902
39,409 Added 1408.97%
42,206 $130,000
Q1 2020

May 14, 2020

BUY
$3.26 - $9.65 $9,118 - $26,991
2,797 New
2,797 $12,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.06B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.